Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Safety in clinical trials

Pharmacovigilance and risk management

12 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Explain pharmacovigilance and how it continues after approval

  • Describe spontaneous reporting and signal detection

  • Outline risk management plans and how trial safety links to post-marketing safety

Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. It covers the whole life of a medicine, from the early clinical trials through years of marketed use.

Why PV continues after approval

Trials involve a limited number of carefully selected people for a limited time. They cannot find rare effects (for example, 1 in 10,000), delayed effects, or effects in groups excluded from trials, such as pregnant women, older people, or those with other conditions. Post-marketing PV fills these gaps.

Sources of safety information

  • Clinical trials, including long-term extensions.
  • Spontaneous reports from health professionals, patients and companies.
  • Registries and electronic health records.
  • Published literature.
  • Regulatory databases such as national pharmacovigilance centres, which in many countries link to the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre).

Signal detection

Analysts review reports for patterns that are more frequent than expected, using clinical review and statistical tools to compare observed and expected reporting. A signal is hypothesis-generating: it requires evaluation, such as a study, before concluding the drug causes harm.

1Collect reports2Detect signals3Evaluate4Act on risk5CommunicatePharmacovigilance
The pharmacovigilance cycle.

Risk management

A risk management plan (RMP) describes known and potential safety concerns, plans to study them further (pharmacovigilance activities), and risk minimisation measures such as restricted prescribing, special labelling, educational materials or required laboratory monitoring.

Why trial staff should care about PV

  • High-quality AE data from trials feed the safety database used throughout the product's life.
  • Accurate MedDRA coding allows events to be compared across studies.
  • Trial teams are often the first to see safety patterns.
  • Reporting suspected reactions also matters once a medicine is in routine use: in many countries, health workers can report to the national pharmacovigilance centre.

Worked example: why rare effects need large numbers

Suppose a drug causes a serious reaction in 1 in 5,000 users.

  • A trial with 1,000 participants would have an expected 0.2 cases, so the effect would most likely be missed.
  • To have a reasonable chance of seeing at least one case, you need roughly 3 times the reciprocal of the rate, the rule of three: 3 × 5,000 = 15,000 participants for about a 95% chance of seeing one or more cases.

This is why post-marketing surveillance of hundreds of thousands of users is needed to find rare reactions that trials cannot detect.

Safety knowledge keeps growing

A drug label is a snapshot. New information from PV can change warnings, restrict use, or lead to withdrawal. Participants and prescribers are entitled to the latest information.

Absence of evidence is not evidence of absence

A trial that finds no serious reactions in a few thousand participants cannot prove a rare serious reaction does not exist.

Check yourself

Find the pharmacovigilance reporting form or system used in your country. Who can report, and what information is needed?

Summary

  • Pharmacovigilance covers detection, assessment, understanding and prevention of drug-related problems throughout a product's life.

  • Trials miss rare, delayed and special-population effects; post-marketing surveillance fills the gap.

  • Signals are hypotheses that require evaluation before conclusions are drawn.

  • Risk management plans set out how known and potential risks are monitored and minimised.

Check your understanding

Question 1
1

Pharmacovigilance primarily deals with:

Question 2
2

A drug reaction occurs in 1 in 5,000 people. To see about one case with high probability, the rule of three suggests about:

Question 3
3

Why can trials miss rare adverse reactions?

Question 4
4

A risk minimisation measure could be:

Question 5
5

MedDRA is used for:

Question 6
6

A safety signal should be treated as:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Safety reporting timelines and oversight committeesMonitoring: visits, remote checks and risk-based approaches